Valiant Laboratories

Valiant Laboratories approved an additional investment of up to ₹60 crore in its wholly owned subsidiary Valiant Advanced Sciences, through 1% optionally convertible redeemable preference shares, to meet working-capital needs and general corporate purposes. The investment was to be made in one or more tranches within 12 months and would leave the subsidiary wholly owned by Valiant Laboratories. VASPL was the group's vehicle for specialty-chemicals expansion and reported FY26 turnover of ₹41.65 crore and net worth of ₹156.18 crore, compared with turnover of ₹2.02 lakh in FY25. The board also approved five-year reappointments for managing director Santosh Vora and independent director Sonal Vira, and recommended the continuation of Shantilal Vora as a non-executive director after he reaches 75, subject to shareholder approval. It approved moving the registered office from Mulund to the Tarapur plant and opening a corporate office in Vikhroli. Valiant Laboratories had reported FY26 consolidated revenue of ₹237.5 crore and a ₹3.27 crore loss.

Powered by Tijori

Aug 10 (Reuters) - Valiant Laboratories Ltd VALO.NS:

• JUNE-QUARTER CONSOL NET PROFIT 211 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.15 BILLION RUPEES

Source text: ID:nBSE2cNf8W

Further company coverage: VALO.NS

(([email protected];;))

Jan 15 (Reuters) - Valiant Laboratories Ltd VALO.NS:

• VALIANT LABORATORIES LTD - RECEIVES NOTICE FOR TOTAL TAX DEMAND OF APPROX. 125.3 MILLION RUPEES

Source text: ID:nBSE16PLbx

Further company coverage: VALO.NS

(([email protected];))

July 9 (Reuters) - Valiant Laboratories Ltd VALO.NS:

• APPROVES RIGHTS ISSUE UP TO 814.7 MILLION RUPEES

Source text: ID:nBSE8VTFNq

Further company coverage: VALO.NS

(([email protected];;))

Nov 6 (Reuters) - Valiant Laboratories Ltd VALO.NS:

• INDIA'S VALIANT LABORATORIES LTD SEPT-QUARTER CONSOL NET PROFIT 7.9 MILLION RUPEES VERSUS PROFIT 86.6 MILLION RUPEES

• VALIANT LABORATORIES LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 595.5 MILLION RUPEES VERSUS 879.6 MILLION RUPEES

Source text for Eikon: ID:nBSEbqk1q4

Further company coverage: VALO.NS

(([email protected];))

BENGALURU, Oct 6 (Reuters) - Shares of Indian pharmaceutical company Valiant Laboratories VALO.NS rose 15.8% in their trading debut on Friday, valuing the company at 5.28 billion rupees ($63.5 million).

The initial public offering of the Mumbai-based maker of paracetamol tablets was oversubscribed 29.8 times, with retail investors bidding 16 times and high net-worth investors 73.6 times.

The offering had fresh issue of shares worth 1.62 billion rupees ($19.5 million) at the top end of the 133-140 rupees price range.

Valiant is involved in the business of manufacturing active pharmaceutical ingredients (API) for pain killer drug Paracetamol.

Valiant competes with larger rivals such as Granules GRAN.NS and Glenmark Life Sciences GLEM.NS in the API market.

Earlier this week, Indian commercial port operator JSW Infrastructure's JSWN.NS listing saw a bumper opening with shares surging more than 32%.

($1 = 83.2025 Indian rupees)

(Reporting by Sethuraman NR and Kashish Tandon in Bengaluru; Editing by Sohini Goswami)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))